REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
2. Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864-84.
3. Luo Y, Zhu H. Immunotherapy for advanced or recurrent hepatocellular carcinoma. World J Gastrointest Oncol. 2023;15:405-24.
4. Zou Y, Wan X, Zhou Q, et al. Mechanisms of drug resistance in hepatocellular carcinoma. Biol Proced Online. 2025;27:19.
5. Lee YR. A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma. J Liver Cancer. 2023;23:316-29.
6. Yuan Z, Yan K, Wang J. Overexpression of integrin β2 improves migration and engraftment of adipose-derived stem cells and augments angiogenesis in myocardial infarction. Ann Transl Med. 2022;10:863.
7. Zhang L, Guo Q, Guan G, Cheng W, Cheng P, Wu A. Integrin beta 5 is a prognostic biomarker and potential therapeutic target in glioblastoma. Front. Oncol. 2019;9:904.
8. Shi W, He J, Huang Y, et al. Integrin β5 enhances the malignancy of human colorectal cancer by increasing the TGF-β signaling. Anticancer Drugs. 2021;32:717-26.
9. Cheng Y, Lin X, Xu H, et al. Integrin β5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis and immunotherapy efficacy in gastric cancer. BMC Gastroenterol. 2024;24:362.
10. Chen Z, Fang Y, Zhong S, Lin S, Yang X, Chen S. ITGB5 is a prognostic factor in colorectal cancer and promotes cancer progression and metastasis through the Wnt signaling pathway. Sci Rep. 2025;15:9225.
11. Lin Z, He R, Luo H, et al. RETRACTED ARTICLE: integrin-β5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating β-catenin stability. J Exp Clin Cancer Res. 2018;37:17.
12. Shi Y, Wang J, Huang G, et al. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma. Hepatol Int. 2022;16:906-17.
13. Shang L, Ye X, Zhu G, et al. Prognostic value of integrin variants and expression in post-operative patients with HBV-related hepatocellular carcinoma. Oncotarget. 2017;8:76816-31.
14. Yang X, Qin C, Zhao B, et al. Long noncoding RNA and circular RNA: two rising stars in regulating epithelial-mesenchymal transition of pancreatic cancer. Front. Oncol. 2022;12:910678.
15. Ma Q, Yang F, Xiao B, Guo X. Emerging roles of circular RNAs in tumorigenesis, progression, and treatment of gastric cancer. J Transl Med. 2024;22:207.
16. Bao Z, Yang Z, Huang Z, Zhou Y, Cui Q, Dong D. LncRNADisease 2.0: an updated database of long non-coding RNA-associated diseases. Nucleic Acids Res. 2019;47:D1034-7.
17. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393-407.
18. Hwang SY, Danpanichkul P, Agopian V, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31 Suppl:S228-54.
19. Li K, Mathew B, Saldanha E, et al. New insights into biomarkers and risk stratification to predict hepatocellular cancer. Mol Med. 2025;31:152.
20. Zhai W, Lai H, Kaya NA, et al. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. Natl Sci Rev. 2022;9:nwab192.
21. Zhu S, Hoshida Y. Molecular heterogeneity in hepatocellular carcinoma. Hepat. Oncol. 2018;5:HEP10.
22. Chen S, Cao Q, Wen W, Wang H. Targeted therapy for hepatocellular carcinoma: challenges and opportunities. Cancer Lett. 2019;460:1-9.
23. Likhitsup A, Razumilava N, Parikh ND. Treatment for advanced hepatocellular carcinoma: current standard and the future. Clin Liver Dis. 2019;13:13-9.
24. Liu P, Kong L, Liu Y, Li G, Xie J, Lu X. A key driver to promote HCC: cellular crosstalk in tumor microenvironment. Front. Oncol. 2023;13:1135122.
25. Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell Int. 2021;21:208.
26. Huang L, Lu Y, He R, et al. N4-acetylcytidine modification of ITGB5 mRNA mediated by NAT10 promotes perineural invasion in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2025;44:103.
27. Wen X, Chen S, Chen X, et al. ITGB5 promotes innate radiation resistance in pancreatic adenocarcinoma by promoting DNA damage repair and the MEK/ERK signaling pathway. Front. Oncol. 2022;12:887068.
28. Liu D, Cao J, Hu K, Peng Z. Integrin β5 interacts with G3BP1 through activating FAK/Src signaling pathway to promote gastric carcinogenesis. Sci Rep. 2025;15:28633.
29. Mccormick B, Craig HE, Chu JY, et al. A negative feedback loop regulates integrin inactivation and promotes neutrophil recruitment to inflammatory sites. J Immunol. 2019;203:1579-88.
30. Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35:347-67.
31. Juratli MA, Zhou H, Oppermann E, et al. Integrin α2 and β1 cross-communication with mTOR/AKT and the CDK-cyclin axis in hepatocellular carcinoma cells. Cancers. 2022;14:2430.
32. Jafarnejad M, Sové RJ, Danilova L, et al. Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. npj Syst Biol Appl. 2019;5:29.
33. Iovanna J, Estaras M, Grasso D, Fernández Zapico ME, Neira JL, Santofimia-castaño P. Oncogenic stress response mechanisms as new therapeutic targets in cancer treatment: A review. Medicine. 2025;104:e42857.
34. Qiu B, Simon MC. Oncogenes strike a balance between cellular growth and homeostasis. Semin Cell Dev Biol. 2015;43:3-10.
35. Spence HJ, Dhillon AS, James M, Winder SJ. Dystroglycan, a scaffold for the ERK-MAP kinase cascade. EMBO Rep. 2004;5:484-9.
36. Quan J, Wan Z, Wu W, et al. Classical biomarkers and non-coding RNAs associated with diagnosis and treatment in gastric cancer. Oncol Res. 2025;33:1069-89.
37. Deng X, Liao T, Xie J, et al. The burgeoning importance of PIWI-interacting RNAs in cancer progression. Sci. China Life Sci. 2023;67:653-62.
38. Xu S, He L, Chen Y, et al. Clinical implications of miR-195 in cancer: mechanisms, potential applications, and therapeutic strategies. J Cancer Res Clin Oncol. 2025;151:148.
39. Chen J, Wang F, Xu H, et al. Long non-coding RNA SNHG1 regulates the Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell. Front. Oncol. 2020;10:552907.
40. Zeng H, Zhou S, Cai W, Kang M, Zhang P. LncRNA SNHG1: role in tumorigenesis of multiple human cancers. Cancer Cell Int. 2023;23:198.
41. Lu Y, Yu Q, Liu JH, et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem. 2003;278:40057-66.
42. Azzi A. SHIP2 inhibition alters redox‐induced PI3K/AKT and MAP kinase pathways via PTEN over‐activation in cervical cancer cells. FEBS Open Bio. 2020;10:2191-205.
43. Huang XX, Zhang Q, Hu H, et al. A novel circular RNA circFN1 enhances cisplatin resistance in gastric cancer via sponging miR‐182‐5p. J Cell Biochem. 2020;122:1009-20.
44. Sameti P, Tohidast M, Amini M, Bahojb Mahdavi SZ, Najafi S, Mokhtarzadeh A. The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target. Cancer Cell Int. 2023;23:134.
45. Wischmann F, Troschel FM, Frankenberg M, et al. Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation. J Cancer Res Clin Oncol. 2023;149:8455-65.
46. Passaro A, Al Bakir M, Hamilton EG, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024;187:1617-35.
47. Piergentili R, Gullo G, Basile G, et al. Circulating miRNAs as a tool for early diagnosis of endometrial cancer-implications for the fertility-sparing process: clinical, biological, and legal aspects. Int J Mol Sci. 2023;24:11356.
48. Samaržija I, Dekanić A, Humphries JD, et al. Integrin crosstalk contributes to the complexity of signalling and unpredictable cancer cell fates. Cancers. 2020;12:1910.
